1,2,3,4-tetrahydroisoquinoline has been researched along with Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, X; Luo, G; Ma, L; Ren, S; Wang, X; Wu, S; Xiang, H | 1 |
| Cui, ZN; Jin, HW; Li, YS; Liao, YX; Liu, XY; Song, GP; Zhao, DS | 1 |
2 other study(ies) available for 1,2,3,4-tetrahydroisoquinoline and Breast Cancer
| Article | Year |
|---|---|
Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Development; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Structure-Activity Relationship; Tetrahydroisoquinolines; Tumor Cells, Cultured | 2021 |
Synthesis and biological evaluation of 2,5-disubstituted furan derivatives as P-glycoprotein inhibitors for Doxorubicin resistance in MCF-7/ADR cell.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Female; Furans; Humans; MCF-7 Cells; Molecular Docking Simulation; Structure-Activity Relationship; Tetrahydroisoquinolines | 2018 |